Imaging of Estrogen Receptors with Iodine-123- Iabeled Estradiol in Primary Breast Cancer Patients.
10.4048/jkbcs.2002.5.2.108
- Author:
Kwang In PARK
1
;
Woo Chul NOH
;
Ryung Ah LEE
;
Chang Woon CHOI
;
Ho Yoon BANG
;
Dae Yong HWANG
;
Dong Wook CHOI
;
Jong Inn LEE
;
Nam Sun PAIK
;
Nan Mo MOON
Author Information
1. Department of Surgery, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Breast cancer;
Estrogen receptor;
Scintigraphy
- MeSH:
Breast Neoplasms*;
Breast*;
Estradiol*;
Estrogens*;
Humans;
Immunohistochemistry;
Negative Staining;
Nuclear Medicine;
Radionuclide Imaging;
Receptors, Estrogen*;
Tomography, Emission-Computed;
Tomography, Emission-Computed, Single-Photon
- From:Journal of Korean Breast Cancer Society
2002;5(2):108-112
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the feasibility of non-invasive imaging of estrogen receptors (ER) in primary breast cancer with iodine-123-labeled ER specific ligand (17alpha,20E)-21-[123I] iodo-19-nonpregna-1,3,5-(10), 20-tetraene-3, 17-diol using conventional nuclear medicine technique. METHODS: Before they underwent surgical management, planar scintigraphy and single-photon emission computed tomography (SPECT) were performed in 18 patients with proven primary breast cancer, after single IV injection of 5~10 mCi I-123-estradiol. The results were compared with those of immunohistochemical staining against ER of the surgical specimens. RESULTS: Planar and SPECT imaging showed hot uptake in nine of eighteen (50%) breast cancer patients. The results of ER immunohistochemistry were all positive in these patients. In the 9 cases of negative scintigraphy, 8 showed negative staining results but one showed positive staining results. Therefore, the overall concordance rate of ER scintigraphy and ER immunohistochemistry was 94.4% (17/18). CONCLUSION: ER scintigraphy using I-123-estradiol is a highly predictable in vivo technique to detect ER-positive breast cancer preoperatively. It has potential application as a re-liable diagnostic modality and indicator of hormone therapy for breast cancer patients.
